HUASPGI@EC2701A

Ascentage Pharma announces removal of 'B' suffix from share name effective June 1st

Ascentage Pharma-B Announces Six Studies Accepted for 2026 ASCO Annual Meeting, Reveals Data on Olverembatinib and Other New Drugs

Apsino's Lisatoclax Included in CSCO Guidelines

Three Key Products of Ascentage Pharma Win Six Clinical Studies at ASCO Annual Meeting

Ascentage Pharma to Present Preclinical Studies at AACR Annual Meeting and Receives 'Buy' Rating

Ascentage Pharma's APG-115 Inclusion in China's CDE Pediatric Anti-Tumor Drug Development Program

CICC Maintains Buy Rating and Sets 71.20 HKD Target Price for Ascletis

Yashen Pharmaceuticals Reports Strong Commercial Performance in 2025 with Total Revenue of 574 Million Yuan

Ascentage Pharma Announces Financial Results and Clinical Development Progress for 2025

ASCENTAGE-B released FY2025 9 Months Earnings on March 25, 2026 (BJT) with actual revenue of HKD 439.11 M and EPS of HKD -2.8345

ASCENTAGE-B released FY2025 Q3 earnings on March 25, 2026 (BJT), actual revenue HKD 186.07 M (forecast HKD 155.02 M), actual EPS HKD -0.9616

ASCENTAGE-B released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 189.28 M (forecast HKD 176.81 M), actual EPS HKD -0.978

ASCENTAGE-B released FY2025 earnings on March 25 After-Market (BJT), actual revenue HKD 627.49 M (forecast HKD 614.16 M), actual EPS HKD -3.814 (forecast HKD -3.2756)

ASCENTAGE-B to release FY2025 earnings on March 26 After-Market (BJT), forecast revenue HKD 621.91 M, EPS HKD -3.1304

Yashen Medicine's New Drug APG-3288 Receives FDA Clinical Approval

Ascletis to Deliver Presentation at J.P. Morgan Healthcare Conference

Yabio Medical Progresses with Phase III Study of Hycamtin Approved Globally by US and EU Authorities

Yabio Pharmaceuticals Presents Lisaftoclax Efficacy Data for Chronic Lymphocytic Leukemia

Yashen Pharmaceuticals' Olverabatinib Granted FDA and EMA Phase III Clinical Trial Approval

Ascentage Pharma to Present Bcl-2 Inhibitor Lisaftoclax Data at ASH Annual Meeting

JOLIMARK

PANGAEA CONNECT

WEILI HOLDINGS

MAN YUE TECH

SMIT

BJ DIGITAL

FY FINANCIAL

NEW GONOW RV

RADIANCE HLDGS

PERFECTECH INTL

AAPG

06855

LABU

SBIO

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) announced that it will present 17 clinical advances at the 31st Congress of the European Hematology Association (EHA2026) in Stockholm from June 11-14, 2026. The presentations will include data on Olverembatinib, China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax, the first China-developed Bcl-2 selective inhibitor. Key abstracts will cover ongoing studies in chronic myeloid leukemia and other hematologic malignancies. Both drugs are currently under investigation and have not yet received FDA approval in the US.

StockTitan

Ascentage Pharma

ASCENTAGE-B

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Ascentage Pharma Group International ADR - W/I

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress | AAPG Stock News

Ascentage Pharma Group International (HK:6855) will present data from six clinical studies at the 2026 ASCO Annual Meeting in Chicago, focusing on three key drug candidates. The presentations include rapid oral and poster formats, showcasing targeted therapies for adult hematologic cancers and pediatric solid tumors. Notable studies feature Olverembatinib for advanced leukemia and Alrizomadlin for pediatric patients with soft-tissue sarcomas. Analysts rate the stock as a Buy with a target price of HK$93.00, reflecting confidence in the company's innovative oncology therapies.

Tip Ranks

Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting

4502

JP Morgan has lowered the target price for Ascentage from 93 yuan to 89 yuan, maintaining an "overweight" rating. It is expected that Takeda Pharmaceutical Company will not exercise its exclusive option for orebatinib before 2027, while assuming that the chronic myeloid leukemia indication will obtain Phase III clinical trial data in 2027, with commercialization delayed until 2028. Looking ahead, orebatinib and lisaftoclax are considered potential growth drugs for the company in the medium to short term

AASTOCKS

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Company

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Morgan Stanley lowers the target price for Ascentage to 89 yuan, reiterates "Overweight" rating

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting | AAPG Stock News

iShares Global Healthcare

VG Health

iShares US Pharma

Health Care Select Sector SPDR

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting | AAPG Stock News

520690

159316

159570

513120

512290

588130

510660

Ascentage Pharma Group International (SEHK:6855) has seen a 13% rise in share price over the past week and 15% over the past month, despite a 6.8% decline over 90 days. The company reported HK$574.12 million in revenue but a net loss of HK$1,242.77 million. Current share price is HK$52.05, significantly below the fair value estimate of HK$91.17, indicating it may be undervalued. However, risks include reliance on a development-stage pipeline and potential pricing pressures in China. Investors are encouraged to explore other opportunities in the healthcare sector.

Simplywall

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum

CICC analyst maintained a Buy rating on Ascentage Pharma Group International yesterday and set a price target of HK$71.20.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Ascentage Pharma Group International has an analyst consensus of Moderate Buy, with a price target consensus of HK$71.20.

CICC Sticks to Their Buy Rating for Ascentage Pharma Group International (6855)

159837

516930

Ascentage-B announced its full-year results for the year ended last December, with a revenue of RMB 574 million, a year-on-year decrease of 41.5%. The loss widened to RMB 1.243 billion, compared to a loss of RMB 405 million in the same period last year; the loss per share was RMB 3.49. No final dividend will be distributed

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

"Performance" Ascentage Pharma-B's losses widened to 1.243 billion RMB last year

IBBQ

PGEN

Precigen Reports Full Year 2025 Financial Results and Business Updates | PGEN Stock News

Invesco Nasdaq Biotechnology ETF

Precigen

Precigen Reports Full Year 2025 Financial Results and Business Updates | PGEN Stock News

HUASPGI@EC2701A(28800.HK)

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress | AAPG Stock News

Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting

Morgan Stanley lowers the target price for Ascentage to 89 yuan, reiterates "Overweight" rating

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting | AAPG Stock News

Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum

CICC Sticks to Their Buy Rating for Ascentage Pharma Group International (6855)

"Performance" Ascentage Pharma-B's losses widened to 1.243 billion RMB last year

Precigen Reports Full Year 2025 Financial Results and Business Updates | PGEN Stock News